Drug-eluting Balloon Catheters Market Analysis

Based on product, the market is classified into coronary artery disease drug-eluting balloon catheters and peripheral vascular disease drug-eluting balloon catheters. The peripheral vascular disease drug-eluting balloon catheters segment generated the highest revenue of USD 353 million in 2024.

• Peripheral vascular disease drug-eluting balloons are particularly effective in treating complex lesions, such as long or diffuse blockages, where traditional stents may be less effective or unsuitable. By releasing therapeutic agents that reduce smooth muscle cell proliferation and prevent restenosis, DEB catheters for PVD help maintain blood flow and improve outcomes. This effectiveness in complex cases has led to the strong adoption of DEB catheters in the peripheral vascular disease segment, contributing significantly to its market share.
  
• Healthcare providers increasingly prefer minimally invasive procedures for PVD due to reduced recovery times, lower complication rates, and enhanced patient comfort. Drug-eluting balloon catheters, which provide both physical expansion and localized drug delivery without leaving behind a permanent implant, align well with these treatment goals. This approach has driven the widespread acceptance of DEB catheters for PVD, supporting the segment’s leading market position.
  

Based on material, the drug-eluting balloon catheters market is classified into polyurethane, nylon, and other materials. The polyurethane segment accounted for USD 225.4 million in market revenue in 2024 and is anticipated to grow at a CAGR of 10.4% between the 2025 to 2034.

• Polyurethane is a versatile, biocompatible material known for its flexibility, durability, and resistance to abrasion, making it an ideal choice for manufacturing DEB catheters. Its superior elasticity and softness allow for precise navigation through complex vascular structures, reducing patient discomfort and minimizing the risk of vascular injury during procedures. These attributes make polyurethane-based catheters the preferred choice in a variety of vascular interventions, ranging from peripheral to coronary applications.
  
• Furthermore, polyurethane’s durability and abrasion resistance are crucial for DEB catheters, which must maintain structural integrity while delivering drugs to vascular walls. These catheters often navigate narrow and intricate pathways in the body, making them susceptible to surface wear. Polyurethane’s ability to withstand abrasion ensures the catheter's longevity and reliability, allowing it to perform effectively even in challenging anatomical regions and during multiple uses.
  

Based on end use, the drug-eluting balloon catheters market is segmented into hospitals and clinics, ambulatory surgical centers, and catheterization laboratories. The hospitals and clinics segment dominated the market in 2024 and is anticipated to reach USD 938.3 million by the end of the forecast period.

• This high market share is attributed to the increasing prevalence of chronic ailments that require surgical interventions, the rising incidence of peripheral and cardiovascular diseases, and the subsequent number of hospital admissions. Peripheral artery disorders are among the major conditions influencing hospital admissions for catheterization procedures among adults. For instance, according to a report published by Frontiers on Cardiovascular Epidemiology and Prevention in 2022, over 238 million people worldwide suffered from peripheral artery disease, contributing to a significant number of deaths globally.
  
• This high prevalence has led to the increased adoption of drug-eluting balloon catheters in hospitals and clinics. The growing demand for minimally invasive surgical interventions, improved surgical care, and catheterization procedures, along with the availability of highly skilled healthcare professionals, are additional factors positively driving the market growth of the hospitals and clinics segment.
  

North America drug-eluting balloon catheters market accounted for USD 272.2 million in market revenue in 2024 and is anticipated to grow at a CAGR of 8.4% between the 2025 to 2034.

• North America holds a significant share of the global drug-eluting balloon (DEB) catheters market, largely due to its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and strong support for minimally invasive procedures. The U.S. experiences a high incidence of peripheral artery disease (PAD) and coronary artery disease (CAD), which drives demand for innovative treatment options like DEB catheters.
  
• Healthcare providers in North America have adopted DEB technology because it offers effective drug delivery with fewer complications compared to traditional stents. Additionally, extensive clinical studies conducted in the region have validated the efficacy of DEB catheters, bolstering their acceptance among interventional cardiologists and vascular specialists.
  

France drug-eluting balloon catheters market is projected to grow remarkably in the coming years.

• French healthcare authorities prioritize minimally invasive treatments, and DEB catheters provide a compelling solution for treating complex vascular blockages, particularly in cases where stents are not ideal.
  
• Increased funding for cardiovascular treatment and research in France has further contributed to the development and adoption of DEB technology. With a well-developed healthcare system and growing awareness among healthcare providers, France is a major player in the European DEB catheters market.
  

Japan holds a dominant position in the Asia Pacific drug-eluting balloon catheters market.

• With one of the highest proportions of elderly individuals worldwide, Japan faces a significant burden of peripheral and coronary artery diseases. DEB catheters offer a minimally invasive treatment that is particularly well-suited for older adults, who may face higher risks from traditional surgical options.
  
• Japanese healthcare providers have increasingly adopted DEB technology, and the Japanese government’s emphasis on quality healthcare access and advanced treatments further promotes the market’s growth. Japan’s support for medical device innovation also facilitates faster regulatory approvals, helping DEB catheters achieve strong market traction.